Abstract

Diabetes is the leading cause of kidney disease, and as the number of individuals with diabetes increases there is a concomitant increase in the prevalence of diabetic kidney disease (DKD). Diabetes contributes to the development of DKD through a number of pathways, including inflammation, oxidative stress, and the gut-kidney axis, which may be amenable to dietary therapy. Resistant starch (RS) is a dietary fibre that alters the gut microbial consortium, leading to an increase in the microbial production of short chain fatty acids. Evidence from animal and human studies indicate that short chain fatty acids are able to attenuate inflammatory and oxidative stress pathways, which may mitigate the progression of DKD. In this review, we evaluate and summarise the evidence from both preclinical models of DKD and clinical trials that have utilised RS as a dietary therapy to limit the progression of DKD.

RAS ID

54202

Document Type

Journal Article

Date of Publication

11-1-2022

Volume

14

Issue

21

PubMed ID

36364808

School

School of Medical and Health Sciences

Creative Commons License

Creative Commons Attribution 4.0 License
This work is licensed under a Creative Commons Attribution 4.0 License.

Publisher

MDPI

Comments

Drake, A. M., Coughlan, M. T., Christophersen, C. T., & Snelson, M. (2022). Resistant starch as a dietary intervention to limit the progression of diabetic kidney disease. Nutrients, 14(21), 4547. https://doi.org/10.3390/nu14214547

Download

Included in

Diseases Commons

Share

 
COinS
 

Link to publisher version (DOI)

10.3390/nu14214547